Society Letters

Endocrine Society NIOSH Hazardous Drug List Comments

June 25, 2020

To: John Howard, MD, MPH, JD, LLM, MBA, NIOSH Docket Office

"We support the intent behind NIOSH’s Hazardous Drug List of keeping workers safe from unnecessary harm, but do not believe that available evidence points to a need for the inclusion of liraglutide. Therefore, we respectfully ask that you remove the drug from the list. "

arrowRead the Full Summary

Last Updated:
Take Action

Make Your Voice Heard

Take Action
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!